Researchers published findings in Advanced Science describing genetically engineered mouse models of gastric cancer designed to mirror the human disease’s histological diversity and “lethal” behavior. The work links a newly described immune checkpoint biology to why gastric tumors ignore PD-1-based therapies. A parallel report extends the mechanism by pointing to VSIR’s role in amplifying AXL signaling, offering a pathway-level explanation for checkpoint resistance and potentially informing next-generation combination strategies in gastric cancer immunotherapy.